Moderna mRNA Vaccine Facility - Operations


Project at a glance


VIC Australia
Operations
MODERNA AUSTRALIA PTY LTD

Contact Details


Craig Neylon
Medtech Industry Advisor
+61 3 9864 6700

The mRNA vaccine facility is being established under a 10-year partnership between Moderna and the Australian and Victorian Governments, and is expected to be the first facility of its kind in the Southern Hemisphere. Moderna will open the southern hemisphere's first mRNA vaccine facility in the Monash Technology Precinct, adjacent to Monash University in Victoria.


The facility will be capable of producing up to 100 million respiratory vaccine doses annually. This will include COVID-19 vaccines as well as mRNA vaccines for other respiratory viruses (subject to regulatory approvals) and provide Australia with an onshore mRNA manufacturing capability in the event of a new pandemic.


Packages related to the operations of the facility that are available for expression of interest include product and service packages for the laboratory, packages related to vaccine product packaging and packages for other auxiliary materials used in quality control, drug substance and drug product.


Click here to visit the Moderna website.


Timing


Moderna has already started to reach out to local industry for some packages. Packages advertised on ICN Gateway are programmed to commence in October 2023, with some packages closing end of 2023 and in Q1 2024. Suppliers are encouraged to express interest as soon as possible


Engaging local and Indigenous suppliers


Moderna is committed to creating sustainable economic development and employment opportunities for local and Indigenous businesses and individuals by maximising their opportunities to participate in the running of the facility.


Moderna will provide full, fair and reasonable opportunity for capable and competitive local and Indigenous suppliers and social enterprises to compete for work or participate in supply chains associated with the project.


Upcoming Events


Moderna Industry Briefing
Date: Thursday, 5th October, 2023
Time: 4pm - 4.30pm AEDT
Location: Online (free)
Registration link: https://events.humanitix.com/moderna-mrna-vaccine-facility-operations-industry-briefing


Expression of Interest (EOI) & Prequalification


Expression of Interest will require experience in servicing and supplying the pharmaceutical industry; quality pre-qualifications and license checks (where relevant); for product packaging, materials must be temperature resistant (to -50C); may be subject to Moderna and regulatory authority audits (where relevant).


HOW TO REGISTER AN EXPRESSION OF INTEREST (EOI)

  • To submit an EOI, companies must have an ICN Gateway company profile. Information on how to register your company on ICN Gateway is detailed below.
  • This is an initial, generic EOI submission only. All companies who submit an EOI will be included in information presented to companies who are short listed to bid for this Project.
  • The services, programmes and initiatives provided by ICN Victoria are aimed at complementing a company's existing Sales, Marketing and Business Development strategy and any EOI submitted should not be considered as an alternative to these activities.


ICN GATEWAY COMPANY REGISTRATION

  • Click here to register your company profile on ICN Gateway.
  • Support and assistance are available through the web links listed below.
  • An ICN Gateway company profile that accurately and effectively summarises your company is critical to using the services of the ICN Group - please ensure that your company invests the time and energy required to represent your company in the most effective manner possible.
  • Companies should ensure that the email notification functionality within their ICN Gateway company profile is activated to include an appropriate level of coverage to Information & Updates, Major Projects and Regional Opportunities.


(1) ICN Gateway Setup Wizard
(2) ICN Gateway User Guide


Share this project on:

FB Twitter LinkedIn

Work Package
Documents
Full Scope EOI
Partial Scope EOI
Status

Full Scope EOI

Closed: 
15 Dec 2023 (AEST)

Partial Scope EOI

Closed: 
15 Dec 2023 (AEST)
  Closed

Full Scope EOI

Closed: 
15 Dec 2023 (AEST)

Partial Scope EOI

Closed: 
15 Dec 2023 (AEST)
  Closed

Full Scope EOI

Closed: 
15 Dec 2023 (AEST)

Partial Scope EOI

Closed: 
15 Dec 2023 (AEST)
  Closed

Full Scope EOI

Closed: 
01 Feb 2024 (AEST)

Partial Scope EOI

Closed: 
01 Feb 2024 (AEST)
  Closed

Full Scope EOI

Closed: 
01 Feb 2024 (AEST)

Partial Scope EOI

Closed: 
01 Feb 2024 (AEST)
  Closed
AccordianPlus Cleaning Material

Full Scope EOI

Closed: 
01 Mar 2024 (AEST)

Partial Scope EOI

Closed: 
01 Mar 2024 (AEST)
  Closed
AccordianPlus Consumables

Full Scope EOI

Closed: 
01 Mar 2024 (AEST)

Partial Scope EOI

Closed: 
01 Mar 2024 (AEST)
  Closed

Full Scope EOI

Closed: 
01 Mar 2024 (AEST)

Partial Scope EOI

Closed: 
01 Mar 2024 (AEST)
  Closed
AccordianPlus Labels

Full Scope EOI

Closed: 
01 Mar 2024 (AEST)

Partial Scope EOI

Closed: 
01 Mar 2024 (AEST)
  Closed
Note: The closing date/s for expressions of interest are subject to change.